CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 25 of 37 entries

View as:

Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT00714584 Org: User:

Start: 05/31/03 End: 06/30/03 Due: 06/30/04

A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy

Phase: N/A Priority: Normal

NCT ID: NCT00424931 Org: User:

Start: 01/31/07 End: 12/31/07 Due: 12/31/08

A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain

Phase: N/A Priority: Normal

NCT ID: NCT00410644 Org: User:

Start: - End: 02/28/99 Due: 02/28/00

A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis

Phase: N/A Priority: Normal

NCT ID: NCT00411164 Org: User:

Start: 11/30/03 End: 05/31/05 Due: 05/31/06

Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)

Phase: N/A Priority: Normal

NCT ID: NCT00410748 Org: User:

Start: - End: 06/30/00 Due: 06/30/01

Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence

Phase: N/A Priority: Normal

NCT ID: NCT00304499 Org: User:

Start: 12/31/95 End: 12/31/96 Due: 12/31/97

An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation

Phase: N/A Priority: Normal

NCT ID: NCT01230762 Org: User:

Start: - End: 04/30/05 Due: 04/30/06

A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg)

Phase: N/A Priority: Normal

NCT ID: NCT00665522 Org: User:

Start: 12/31/07 End: 09/30/08 Due: 09/30/09

Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder

Phase: N/A Priority: Normal

NCT ID: NCT00269815 Org: User:

Start: - End: 12/31/99 Due: 12/31/00

An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg

Phase: N/A Priority: Normal

NCT ID: NCT00398957 Org: User:

Start: - End: 09/30/98 Due: 09/30/99

Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00269737 Org: User:

Start: 05/31/86 End: 02/29/88 Due: 02/28/89

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.

Phase: N/A Priority: Normal

NCT ID: NCT00211107 Org: User:

Start: 06/30/03 End: 06/30/04 Due: 06/30/05

A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant

Phase: N/A Priority: Normal

NCT ID: NCT00650182 Org: User:

Start: 01/31/03 End: 07/31/03 Due: 07/31/04

A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

Phase: N/A Priority: Normal

NCT ID: NCT00269802 Org: User:

Start: - End: 02/28/99 Due: 02/28/00

Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis

Phase: N/A Priority: Normal

NCT ID: NCT00396422 Org: User:

Start: 09/30/06 End: 03/31/07 Due: 03/31/08

A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain

Phase: N/A Priority: Normal

NCT ID: NCT00411307 Org: User:

Start: - End: 10/31/01 Due: 10/31/02

Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00269763 Org: User:

Start: 10/31/87 End: 04/30/88 Due: 04/30/89

A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children

Phase: N/A Priority: Normal

NCT ID: NCT00269789 Org: User:

Start: 03/31/98 End: 05/31/98 Due: 05/31/99

A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain

Phase: N/A Priority: Normal

NCT ID: NCT00411034 Org: User:

Start: - End: 09/30/99 Due: 09/30/00

An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients

Phase: N/A Priority: Normal

NCT ID: NCT00666393 Org: User:

Start: 10/31/08 End: 12/31/10 Due: 12/31/11

A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump

Phase: N/A Priority: Normal

NCT ID: NCT00264485 Org: User:

Start: 03/31/04 End: 04/30/05 Due: 04/30/06

Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain

Phase: N/A Priority: Normal

NCT ID: NCT00410787 Org: User:

Start: - End: 04/30/02 Due: 04/30/03

An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg

Phase: N/A Priority: Normal

NCT ID: NCT00399295 Org: User:

Start: - End: 06/30/97 Due: 06/30/98

Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT00714558 Org: User:

Start: 04/30/03 End: 05/31/03 Due: 05/31/04

An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

Phase: N/A Priority: Normal

NCT ID: NCT00269776 Org: User:

Start: 11/30/98 End: 01/31/99 Due: 01/31/00

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers	NCT00714584	Alza Corporation, DE, USA	user2@example.com	None	2003-05-31	2003-06-30	2004-06-30	-	-	2025-07-14
A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy	NCT00424931	Alza Corporation, DE, USA	user2@example.com	None	2007-01-31	2007-12-31	2008-12-31	-	-	2025-07-14
A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain	NCT00410644	Alza Corporation, DE, USA	user2@example.com	None	-	1999-02-28	2000-02-28	-	-	2025-07-14
A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis	NCT00411164	Alza Corporation, DE, USA	user2@example.com	None	2003-11-30	2005-05-31	2006-05-31	-	-	2025-07-14
Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)	NCT00410748	Alza Corporation, DE, USA	user2@example.com	None	-	2000-06-30	2001-06-30	-	-	2025-07-14
Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence	NCT00304499	Alza Corporation, DE, USA	user2@example.com	None	1995-12-31	1996-12-31	1997-12-31	-	-	2025-07-14
An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation	NCT01230762	Alza Corporation, DE, USA	user2@example.com	None	-	2005-04-30	2006-04-30	-	-	2025-07-14
A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg)	NCT00665522	Alza Corporation, DE, USA	user2@example.com	None	2007-12-31	2008-09-30	2009-09-30	-	-	2025-07-14
Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder	NCT00269815	Alza Corporation, DE, USA	user2@example.com	None	-	1999-12-31	2000-12-31	-	-	2025-07-14
An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg	NCT00398957	Alza Corporation, DE, USA	user2@example.com	None	-	1998-09-30	1999-09-30	-	-	2025-07-14
Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer	NCT00269737	Alza Corporation, DE, USA	user2@example.com	None	1986-05-31	1988-02-29	1989-02-28	-	-	2025-07-14
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.	NCT00211107	Alza Corporation, DE, USA	user2@example.com	None	2003-06-30	2004-06-30	2005-06-30	-	-	2025-07-14
A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant	NCT00650182	Alza Corporation, DE, USA	user2@example.com	None	2003-01-31	2003-07-31	2004-07-31	-	-	2025-07-14
A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder	NCT00269802	Alza Corporation, DE, USA	user2@example.com	None	-	1999-02-28	2000-02-28	-	-	2025-07-14
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis	NCT00396422	Alza Corporation, DE, USA	user2@example.com	None	2006-09-30	2007-03-31	2008-03-31	-	-	2025-07-14
A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain	NCT00411307	Alza Corporation, DE, USA	user2@example.com	None	-	2001-10-31	2002-10-31	-	-	2025-07-14
Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer	NCT00269763	Alza Corporation, DE, USA	user2@example.com	None	1987-10-31	1988-04-30	1989-04-30	-	-	2025-07-14
A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children	NCT00269789	Alza Corporation, DE, USA	user2@example.com	None	1998-03-31	1998-05-31	1999-05-31	-	-	2025-07-14
A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain	NCT00411034	Alza Corporation, DE, USA	user2@example.com	None	-	1999-09-30	2000-09-30	-	-	2025-07-14
An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients	NCT00666393	Alza Corporation, DE, USA	user2@example.com	None	2008-10-31	2010-12-31	2011-12-31	-	-	2025-07-14
A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump	NCT00264485	Alza Corporation, DE, USA	user2@example.com	None	2004-03-31	2005-04-30	2006-04-30	-	-	2025-07-14
Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain	NCT00410787	Alza Corporation, DE, USA	user2@example.com	None	-	2002-04-30	2003-04-30	-	-	2025-07-14
An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg	NCT00399295	Alza Corporation, DE, USA	user2@example.com	None	-	1997-06-30	1998-06-30	-	-	2025-07-14
Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers	NCT00714558	Alza Corporation, DE, USA	user2@example.com	None	2003-04-30	2003-05-31	2004-05-31	-	-	2025-07-14
An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder	NCT00269776	Alza Corporation, DE, USA	user2@example.com	None	1998-11-30	1999-01-31	2000-01-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance